<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015196</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 99/10-L</org_study_id>
    <nct_id>NCT01015196</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation</brief_title>
  <acronym>AML2001</acronym>
  <official_title>AML 2001: a Phase III Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation (ASCT) as Consolidation Strategy for Adults Aged 15 to 60 With Acute Myeloid Leukemia (AML) in First Complete Remission (CR).rémission complète d'Une Leucémie Aiguë Myéloblastique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First randomization:

      After inclusion Use of Daunorubicin (arm D) or Idarubicin (arm I) as anthracyclin during all
      courses of chemotherapy (induction, consolidation courses before ASCT)

      Second randomization:

      After achieving 1st CR: all patients received non intensive consolidation course Familial HLA
      typing required for all patients

      Patients with HLA-identical sibling:

      Patients with very good prognostic factors (CBF leukemias, WBC &lt; 30 giga/l at diagnosis, 1st
      CR after one induction course) = arm C: no allogeneic stem cell transplantation in 1st CR;
      received 2 more courses of intensive consolidation chemotherapy All others patients received
      an allogeneic transplant For patients aged less than 51 = arm M: upfront myeloablative
      conditioning regimen For patients aged over 51 and less than 61= arm m: intensive
      chemotherapy consolidation course.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">832</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Idarubicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Daunorubicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zavedos</intervention_name>
    <arm_group_label>Idarubicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerubidine</intervention_name>
    <arm_group_label>Daunorubicine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 15 to 60 years

          -  Diagnosis untreated AML (FAB 0 to 2, 4 to 7): more than 20% marrow blasts according to
             WHO classification

          -  Signed informed consent required

        Exclusion Criteria:

          -  AML3 subtype

          -  Previous diagnosis of myelodysplastic syndrome (MDS) or myeloproliferative disease;
             patients with previous chemotherapy or radiotherapy were eligible if they had no
             previous diagnosis of MDS

          -  Isolated extramedullary disease

          -  Inadequate performance status (≥ 3), cardiac function (LVEF &lt; 40%, severe arythmia or
             unstable coronary disease), renal function (creatininine &gt; 150 µmol/l), liver
             functional tests (bilirubin &gt; 35 µmol/l, liver enzymes &gt; 4 times normal values); life
             expectancy &lt; 3 months

          -  Informed consent refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>November 17, 2009</last_update_submitted>
  <last_update_submitted_qc>November 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Cellule de promotion de la recherche clinique</name_title>
    <organization>Nantes University Hospital</organization>
  </responsible_party>
  <keyword>acute myeloid leukemia in first complete remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

